Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease

Sep 30, 2026

Uploaded by Franzy

Tau pathology serves as a defining hallmark of Alzheimer’s disease, and hyperphosphorylated Tau (p-Tau) functions as a core biomarker for early diagnosis and disease monitoring. Distinct p-Tau epitopes improve diagnostic precision and underpin modern AD diagnostic strategies. Conventional fluid-based immunoassays such as ELISA, CLEIA, and SIMOA remain central due to sensitivity and clinical validation. Emerging tau-biology advances and post-translational modification research drive next-generation electrochemical, optical, and nanostructured biosensors enabling real-time, label-free, attomolar detection in biofluids and live cell models.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages19

Reading Time48 min

AccessFree to download

Introduction

Tau pathology and hyperphosphorylated Tau as biomarkers

Post-translational modifications of Tau

Biosensor-based diagnostic technologies

Classical fluid-based immunoassays

Next-generation biosensors and detection performance

Affinity reagents for biosensor enhancement

Shabana et al. Alzheimer's Research & Therapy (2026) 18:5 [https://doi.org/10.1186/s13195-025-01932-2](https://doi.org/10.1186/s13195-025-01932-2) Alzheimer's Research & Therapy REVIEW Open Access Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease Samah Shabana 1,2, Hamed I. Hamouda3, Angyang Shang 1,2, Shuai Shao 1,2, Jinyuan Zhao 1, Hong Yuan 1* and Bo Liu 1,2* Abstract Tau pathology is a defining feature of Alzheimer's disease (AD), with hyperphosphorylated Tau (p-Tau) emerging as a central biomarker for early diagnosis and disease monitoring. Various p-Tau epitopes have demonstrated superior diagnostic precision and now form the molecular basis of updated AD diagnostic frameworks. Classical immunoassays such as enzyme-linked immunosorbent assay (ELISA), chemiluminescent enzyme immunoassay (CLEIA), and single molecule array (SIMOA) remain central to fluid based detection, offering high sensitivity and clinical validation. Recent advances in tau biology, especially in post-translational modifications, have driven the development of next generation biosensors. Electrochemical, optical, and nanostructured platforms now enable real-time, label-free, and attomolar level detection of p-Tau in biofluids and live cell models. These systems are increasingly portable and suitable for point of care or in vivo applications. This review highlights the evolution of p-Tau detection technologies, from benchmark immunoassays to cutting edge biosensors. Special attention is given to advanced affinity reagents, including aptamers, synthetic peptides, and antibody mimetics, which enhance biosensor specificity, stability, and translational potential. Together, these innovations are redefining AD diagnostics, enabling early intervention and more effective disease monitoring. Keywords Tau protein, Hyperphosphorylated Tau, Alzheimer's disease biomarkers, Biosensors *Correspondence: Hong Yuan [zhaojingyuanlab@outlook.com](zhaojingyuanlab@outlook.com)[ ](zhaojingyuanlab@outlook.com)Bo Liu [l bo@dl ut.edu.cn](l bo@dl ut.edu.cn) Full list of author information is available at the end of the article © The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/. Shabana et al. Alzheimer's Research & Therapy (2026) 18:5 Page 2 of 19 Graphical Abstract Introduction Alzheimer's disease (AD) is a devastating neurodegenerative condition characterized by progressive cognitive decline, synaptic dysfunction, and neuronal loss [1, 2]. Affecting over 55 million individuals worldwide, with this number projected to nearly triple by 2050. AD represents a growing global crisis, placing a tremendous social and economic burden on patients, families, and healthcare systems [3]. Pathologically, the disease is marked by the extracellular accumulation of amyloid-β 1–42 (Aβ) plaques and the intracellular formation of neurofibrillary tangles (NFTs), primarily composed of hyp

FAQs

Why is hyperphosphorylated Tau (p-Tau) important in Alzheimer’s disease diagnostics?

Hyperphosphorylated Tau is highlighted as a central biomarker for early diagnosis and ongoing disease monitoring, with diagnostic frameworks built around specific p-Tau epitopes.

Which classical fluid-based detection methods are emphasized?

The abstract names ELISA, CLEIA, and SIMOA as core approaches that provide high sensitivity and clinical validation for p-Tau detection.

What capabilities do recent biosensors add compared with classical immunoassays?

Recent advances enable electrochemical, optical, and nanostructured biosensors for real-time, label-free, and attomolar-level detection of p-Tau in biofluids and live cell models.

Sep 30, 2026

Uploaded by Franzy